UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 27,856 Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC trimmed its holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) by 12.8% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 189,739 shares of the biopharmaceutical company’s stock after selling 27,856 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in ACADIA Pharmaceuticals were worth $2,918,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of the business. Park Place Capital Corp bought a new position in shares of ACADIA Pharmaceuticals in the third quarter worth about $25,000. Values First Advisors Inc. bought a new stake in shares of ACADIA Pharmaceuticals in the third quarter valued at about $27,000. Quest Partners LLC boosted its stake in shares of ACADIA Pharmaceuticals by 42.3% during the third quarter. Quest Partners LLC now owns 3,520 shares of the biopharmaceutical company’s stock valued at $54,000 after purchasing an additional 1,047 shares in the last quarter. Stonepine Capital Management LLC purchased a new position in ACADIA Pharmaceuticals during the second quarter valued at approximately $81,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its holdings in ACADIA Pharmaceuticals by 21.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,999 shares of the biopharmaceutical company’s stock worth $94,000 after buying an additional 1,066 shares during the period. Hedge funds and other institutional investors own 96.71% of the company’s stock.

Insider Buying and Selling

In other ACADIA Pharmaceuticals news, insider James Kihara sold 4,073 shares of the stock in a transaction dated Tuesday, November 19th. The shares were sold at an average price of $16.81, for a total value of $68,467.13. Following the completion of the sale, the insider now owns 19,863 shares in the company, valued at approximately $333,897.03. This represents a 17.02 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Brendan Teehan sold 10,329 shares of the firm’s stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $16.81, for a total transaction of $173,630.49. Following the completion of the transaction, the chief operating officer now directly owns 62,105 shares in the company, valued at $1,043,985.05. This trade represents a 14.26 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 24,661 shares of company stock worth $414,551. 28.30% of the stock is owned by corporate insiders.

ACADIA Pharmaceuticals Stock Performance

Shares of NASDAQ ACAD opened at $17.26 on Friday. The firm has a fifty day moving average of $16.00 and a 200 day moving average of $16.15. The firm has a market cap of $2.87 billion, a PE ratio of 22.13 and a beta of 0.40. ACADIA Pharmaceuticals Inc. has a one year low of $14.15 and a one year high of $32.59.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last issued its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $0.20 earnings per share for the quarter, beating analysts’ consensus estimates of $0.14 by $0.06. ACADIA Pharmaceuticals had a net margin of 13.83% and a return on equity of 25.83%. The firm had revenue of $250.40 million for the quarter, compared to analyst estimates of $248.83 million. During the same period last year, the company posted ($0.40) EPS. ACADIA Pharmaceuticals’s quarterly revenue was up 18.3% compared to the same quarter last year. On average, equities analysts predict that ACADIA Pharmaceuticals Inc. will post 0.73 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

ACAD has been the subject of a number of recent research reports. StockNews.com downgraded shares of ACADIA Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Thursday, November 14th. HC Wainwright reissued a “buy” rating and issued a $27.00 price objective on shares of ACADIA Pharmaceuticals in a research report on Thursday, November 7th. Raymond James restated a “market perform” rating on shares of ACADIA Pharmaceuticals in a research note on Thursday, October 10th. Finally, Needham & Company LLC restated a “buy” rating and set a $28.00 price target on shares of ACADIA Pharmaceuticals in a research note on Thursday, November 7th. Six equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. According to data from MarketBeat.com, ACADIA Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $25.60.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.